4.7 Review

Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention

期刊

AGEING RESEARCH REVIEWS
卷 74, 期 -, 页码 -

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.arr.2021.101544

关键词

Alzheimer; Biomarker; A beta; Tau; CSF; Blood; Imaging

资金

  1. National Natural Science Foundation of China [92049107, 31771114, 31929002]
  2. Ministry of Science and Technology of China [2016YFC1305800]
  3. Sanming Project of Medicine in Shenzhen [SZSM201801014]
  4. Innovative Research Groups of the Na-tional Natural Science Foundation of China [81721005]
  5. Academic Frontier Youth Team Project

向作者/读者索取更多资源

Alzheimer's disease is a neurodegenerative disease associated with aging and is considered a global public health threat. The disease is characterized by specific histological features and clinical symptoms, but drug therapies targeting these features have proven to be ineffective. Early diagnosis and treatment are crucial, and the use of reliable biomarkers can aid in accurate diagnosis and evaluation of related pathologies.
Alzheimer's disease (AD), being the number one in terms of dementia burden, is an insidious age-related neurodegenerative disease and is presently considered a global public health threat. Its main histological hallmarks are the A beta senile plaques and the P-tau neurofibrillary tangles, while clinically it is marked by a progressive cognitive decline that reflects the underlying synaptic loss and neurodegeneration. Many of the drug therapies targeting the two pathological hallmarks namely A beta and P-tau have been proven futile. This is probably attributed to the initiation of therapy at a stage where cognitive alterations are already obvious. In other words, the underlying neuropathological changes are at a stage where these drugs lack any therapeutic value in reversing the damage. Therefore, there is an urgent need to start treatment in the very early stage where these changes can be reversed, and hence, early diagnosis is of primordial importance. To this aim, the use of robust and informative biomarkers that could provide accurate diagnosis preferably at an earlier phase of the disease is of the essence. To date, several biomarkers have been established that, to a different extent, allow researchers and clinicians to evaluate, diagnose, and more specially exclude other related pathologies. In this study, we extensively reviewed data on the currently explored biomarkers in terms of AD pathology-specific and nonspecific biomarkers and highlighted the recent developments in the diagnostic and theragnostic domains. In the end, we have presented a separate elaboration on aspects of future perspectives and concluding remarks.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据